A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma.
… -label study (NCT04337970) of talazoparib plus axitinib in previously treated ccRCC patients.
In the phase Ib dose escalation, patients must have been previously treated with a PD-1/…
In the phase Ib dose escalation, patients must have been previously treated with a PD-1/…
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations
R Iacovelli, C Ciccarese, G Procopio, S Astore… - Cancer Treatment …, 2022 - Elsevier
… of axitinib in mRCC patients previously treated with … Talazoparib is under evaluation in
a phase Ib/II trial in combination with axitinib in previously treated mRCC patients (NCT04337970)…
a phase Ib/II trial in combination with axitinib in previously treated mRCC patients (NCT04337970)…
The emerging role of poly (ADP-Ribose) polymerase inhibitors as effective therapeutic agents in renal cell carcinoma
JP Pletcher, S Bhattacharjee, JP Doan, R Wynn… - Frontiers in …, 2021 - frontiersin.org
… talazoparib were the most effective in achieving >50% suppression of cell survival with 72 h
treatment… ipilimumab; pembrolizumab plus axitinib; avelumab plus axitinib; or atezolizumab …
treatment… ipilimumab; pembrolizumab plus axitinib; avelumab plus axitinib; or atezolizumab …
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
Y Tai, A Chow, S Han, C Coker, W Ma, Y Gu… - EMBO Molecular …, 2024 - embopress.org
… Since axitinib is already FDA-approved for renal cancer treatment, … efficacy and durability of
PARPi treatment in breast cancer. … talazoparib in a Phase Ib/II clinical trial (NCT04337970) in …
PARPi treatment in breast cancer. … talazoparib in a Phase Ib/II clinical trial (NCT04337970) in …
The frontline immunotherapy-based treatment of advanced clear cell renal cell carcinoma: current evidence and clinical perspective
IH Kim, HJ Lee - Biomedicines, 2022 - mdpi.com
… -PD-1 monoclonal antibody) plus axitinib (Pem+Axi) with sunitinib for previously untreated
… telaglenastat with cabozantinib + placebo in previously treated patients, did not show clinical …
… telaglenastat with cabozantinib + placebo in previously treated patients, did not show clinical …
[HTML][HTML] All Topics
B Goueli - biopharmatrend.com
… For example, consider clinical trial NCT04337970 exploring the efficacy of talazoparib and
axitinib in patients with previously treated metastatic clear cell renal cell cancer. One of the …
axitinib in patients with previously treated metastatic clear cell renal cell cancer. One of the …
Signatures of defective DNA repair and replication in early-onset renal cancer patients referred for germline genetic testing
… Early onset renal cell carcinoma (eoRCC) in patients under the age of 60 has been
increasing in frequency over the past decade (1). In the United States alone, the most recent …
increasing in frequency over the past decade (1). In the United States alone, the most recent …
Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing
… Early onset renal cell carcinoma (eoRCC) in patients under the age of 60 has been
increasing in frequency over the past decade [1]. In the United States alone, the most recent …
increasing in frequency over the past decade [1]. In the United States alone, the most recent …